Enoxaparin sodium

Generic Name: Enoxaparin sodium

Brand Names: Lovenox, Inhixa

Drug Type: Small Molecule

CAS Number: 9005-49-6

Unique Ingredient Identifier: E47C0NF7LV

Background: Enoxaparin is a common low-molecular-weight heparin (LMWH) used in the prevention and management of various thromboembolic disorders. Initially approved by the FDA in 1993, it is administered by a subcutaneous or intravenous injection and marketed by several pharmaceutical companies. Enoxaparin markedly reduces the incidence of venous thromboembolism in hospitalized patients when compared to unfractionated heparin, without increasing the risk of serious bleeding.

Indication: Enoxaparin is indicated for the prevention of ischemic complications in unstable angina and in non Q-wave myocardial infarction; it is indicated in conjunction with percutaneous intervention and/or other treatment for the management of acute ST elevation myocardial infarction.

Enoxaparin is also indicated in the prophylaxis of DVT in abdominal surgery, hip replacement, knee replacement, or medical patients with severely restricted mobility during acute illness. Additionally, enoxaparin is indicated for the inpatient treatment of DVT with or without pulmonary embolism and the treatment of outpatient DVT without pulmonary embolism.

Associated Conditions: Acute Coronary Syndrome (ACS), Acute Myocardial Infarction With ST Segment Elevation, Deep Vein Thrombosis, Ischemic complications caused by non-q wave myocardial infarction, Ischemic complications caused by unstable angina

Associated Therapies: Percutaneous Coronary Intervention (PCI)

Clinical Trials

A Healthy Volunteer PK/PD, Safety and Tolerability Study of Second Generation Andexanet Alfa

Phase 1

Completed

Conditions: Bleeding

Interventions: Drug: Apixaban 5 MG
Drug: Rivaroxaban 20 MG
Biological: Andexanet alfa (Gen 1 Process 2)
Drug: Enoxaparin sodium
Drug: Edoxaban 60 MG
Biological: Andexanet alfa (Gen 1 Process 3)
Biological: Andexanet alfa (Gen 2)
Drug: Apixaban 10 MG
Drug: Rivaroxaban 10 MG

First Posted Date: 2017-03-20

Last Posted Date: 2023-08-08

Lead Sponsor: Portola Pharmaceuticals

Target Recruit Count: 153

Registration Number: NCT03083704

Locations: 🇺🇸
West Coast Clinical Trials, Cypress, California, United States

Evaluation of the Efficacy of an inTerdialytic "Ethanol 40% v/v - enoxapaRin 1000 U/mL" Lock solutioN to Prevent Tunnelled Catheter Infections in Chronic Hemodialysis Patients

Phase 3

Recruiting

Conditions: Tunnelled Hemodialysis Catheter Infection

Interventions: Drug: enoxaparin
Drug: Ethanol

First Posted Date: 2017-03-17

Last Posted Date: 2023-12-08

Lead Sponsor: University Hospital, Clermont-Ferrand

Target Recruit Count: 400

Registration Number: NCT03083184

Locations: 🇫🇷
CHU Clermont-Ferrand, Clermont-Ferrand, France

Timing of VTE Prophylaxis in TBI

Phase 4

Withdrawn

Conditions: TBI (Traumatic Brain Injury)
VTE (Venous Thromboembolism)

Interventions: Drug: Enoxaparin Sodium 150 MG/ML Prefilled Syringe
Drug: Heparin

First Posted Date: 2017-03-16

Last Posted Date: 2019-08-16

Lead Sponsor: Loyola University

Registration Number: NCT03081169

Locations: 🇺🇸
Loyola University Medical Center, Maywood, Illinois, United States

Catheter-Related Early Thromboprophylaxis With Enoxaparin (CRETE) Trial

Phase 2

Terminated

Conditions: Deep Venous Thrombosis

Interventions: Drug: Enoxaparin

First Posted Date: 2016-12-28

Last Posted Date: 2020-07-13

Lead Sponsor: Yale University

Target Recruit Count: 51

Registration Number: NCT03003390

Locations: 🇺🇸
Saint Louis Children's Hospital-Washington University School of Medicine-, Saint Louis, Missouri, United States
🇺🇸
Maria Fareri Children's Hospital, Valhalla, New York, United States
🇺🇸
Yale University Yale New Haven Health, New Haven, Connecticut, United States

and more 3 locations

A Study to Evaluate Safety of Single Doses of BMS-986177 in Patients With End Stage Renal Disease (ESRD) Treated With Hemodialysis

Phase 1

Completed

Conditions: Antithrombotic

Interventions: Drug: Enoxaparin
Drug: unfractionated heparin (UFH)
Drug: BMS-986177

First Posted Date: 2016-12-22

Last Posted Date: 2020-12-29

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 32

Registration Number: NCT03000673

Locations: 🇺🇸
Davita Clinical Research, Minneapolis, Minnesota, United States
🇺🇸
Orlando Clinical Research Center, Orlando, Florida, United States

Study to Assess the Safety, Pharmacokinetics/Dynamics of DS-1040b in Subjects With Acute Submassive Pulmonary Embolism

Phase 1

Completed

Conditions: Pulmonary Embolism
Thrombotic Disease

Interventions: Drug: DS-1040b
Drug: Placebo
Drug: Enoxaparin

First Posted Date: 2016-10-04

Last Posted Date: 2023-04-19

Lead Sponsor: Daiichi Sankyo

Target Recruit Count: 134

Registration Number: NCT02923115

Locations: 🇳🇱
Albert Schweitzer Hospital, Dordrecht, Netherlands
🇺🇸
University of California, San Diego (UCSD) Medical Center, San Diego, California, United States
🇺🇸
Duke University Medical Center (DUMC), Durham, North Carolina, United States

and more 43 locations

Topical Tranexamic Acid and Floseal® in Total Knee Arthroplasty

Phase 4

Conditions: Osteoarthritis, Knee

Interventions: Drug: Topical tranexamic acid
Drug: Floseal®
Drug: Enoxaparin

First Posted Date: 2016-08-12

Last Posted Date: 2016-08-12

Lead Sponsor: Chang Gung Memorial Hospital

Target Recruit Count: 90

Registration Number: NCT02865174

Locations: 🇨🇳
Kaohsiung Chang Gung Memorial Hospital, Koahsiung, Taiwan

Bemiparin Versus Enoxaparin in the Prevention of Venous Thromboembolism Among ICU Patients

Not Applicable

Completed

Conditions: Venous Thromboembolism

Interventions: Drug: Bemiparin
Drug: Enoxaparin

First Posted Date: 2016-06-09

Last Posted Date: 2016-06-10

Lead Sponsor: Mohamed Sayed Mohamed Abbas

Target Recruit Count: 100

Registration Number: NCT02795065

Direct Oral Anticoagulants (DOACs) Versus LMWH +/- Warfarin for VTE in Cancer

Not Applicable

Completed

Conditions: Cancer
Venous Thromboembolism
Deep Vein Thrombosis (DVT)
Pulmonary Embolism (PE)
Blood Clot

Interventions: Drug: Rivaroxaban
Drug: Warfarin
Drug: Apixaban
Drug: Dalteparin
Drug: Edoxaban
Drug: Enoxaparin
Drug: Dabigatran
Drug: Fondaparinux

First Posted Date: 2016-04-20

Last Posted Date: 2023-10-03

Lead Sponsor: Alliance Foundation Trials, LLC.

Target Recruit Count: 811

Registration Number: NCT02744092

Locations: 🇺🇸
Washington Hospital, Fremont, California, United States
🇺🇸
Memorial Cancer Institute at Memorial Regional Hospital, Hollywood, Florida, United States
🇺🇸
Saint Joseph's Medical Center, Stockton, California, United States

and more 145 locations

Study to Assess Safety, Tolerability, and Efficacy of GMI-1271 in Patients With Calf-level Deep Venous Thrombosis (DVT)

Phase 1

Terminated

Conditions: Deep Venous Thrombosis

Interventions: Drug: Enoxaparin Sodium (Lovenox®)
Drug: GMI-1271

First Posted Date: 2016-04-20

Last Posted Date: 2019-06-14

Lead Sponsor: GlycoMimetics Incorporated

Target Recruit Count: 2

Registration Number: NCT02744833

Locations: 🇺🇸
University of Michigan, Ann Arbor, Michigan, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy